CARDINAL HEALTH, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 103.1 USD | -0.29% |
|
-3.43% | +2.05% |
Financials (USD)
| Sales 2024 * | 226B | Sales 2025 * | 239B | Capitalization | 25.14B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.21B | Net income 2025 * | 1.54B | EV / Sales 2024 * | 0.11 x |
| Net cash position 2024 * | 436M | Net cash position 2025 * | 1.34B | EV / Sales 2025 * | 0.1 x |
| P/E ratio 2024 * |
18.1
x | P/E ratio 2025 * |
15.4
x | Employees | 47,520 |
| Yield 2024 * |
1.96% | Yield 2025 * |
1.99% | Free-Float | 74.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cardinal Health, Inc.
More recommendations
More press releases
| 1 day | -0.60% | ||
| 1 week | -3.55% | ||
| Current month | -7.62% | ||
| 1 month | -6.88% | ||
| 3 months | -1.12% | ||
| 6 months | +12.37% | ||
| Current year | +2.55% |
1 week
101.23
108.42
1 month
101.23112.58
Current year
100.36116.04
1 year
77.56116.04
3 years
45.85116.04
5 years
39.05116.04
10 years
39.05116.04
| Managers | Title | Age | Since |
|---|---|---|---|
Jason Hollar
CEO | Chief Executive Officer | 51 | 20-04-26 |
Aaron Alt
DFI | Director of Finance/CFO | 53 | 23-02-09 |
Michelle Greene
CTO | Chief Tech/Sci/R&D Officer | 54 | 20-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 22-09-05 | |
| Director/Board Member | 71 | 13-09-11 | |
Gregory Kenny
CHM | Chairman | 71 | 06-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 102.9 | -0.47% | 866 486 |
| 24-04-23 | 103.4 | +0.53% | 2,477,426 |
| 24-04-22 | 102.8 | -4.95% | 5,287,253 |
| 24-04-19 | 108.2 | +2.07% | 1,486,096 |
| 24-04-18 | 106 | -0.49% | 1,541,130 |
Delayed Quote Nyse, April 23, 2024 at 04:00 pm EDT
More quotes
Cardinal Health, Inc. is specialized in the distribution of products and health services to pharmacies, hospitals and medical practices. Net sales break down by activity as follows:
- distribution of pharmaceutical products (92.7%);
- distribution of medical, surgical and laboratory products (7.3%). The group also develops a manufacturing of medical and surgical products activity (masks, overalls, gloves, diagnostic products, products of aspiration and collection of liquids, radiology intervention, respiratory assistance, etc.).
The United States accounts for 97.7% of net sales.
Sector
Pharmaceuticals
Calendar
2024-05-01
- Q3 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
103.4
USD
Average target price
112.9
USD
Spread / Average Target
+9.25%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.55% | 25.14B | |
| +14.88% | 69.91B | |
| +5.62% | 8.32B | |
| +5.20% | 8.07B | |
| -20.43% | 7.97B | |
| +0.85% | 4.56B | |
| +16.98% | 4.31B | |
| -2.00% | 3.99B | |
| -2.41% | 3.87B | |
| +21.87% | 3.63B |
- Stock Market
- Equities
- CAH Stock
